Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

33.3%

1 terminated/withdrawn out of 3 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
3(100.0%)
3Total
Phase 1(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT06735820Phase 1Not Yet Recruiting

Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNST

Role: lead

NCT02076906Phase 1Completed

MR-guided High Intensity Focused Ultrasound (HIFU) on Pediatric Solid Tumors

Role: lead

NCT02536183Phase 1Terminated

A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors

Role: lead

All 3 trials loaded